Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more
Getein Biotech Inc (603387) - Total Assets
Latest total assets as of September 2025: CN¥3.84 Billion CNY
Based on the latest financial reports, Getein Biotech Inc (603387) holds total assets worth CN¥3.84 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Getein Biotech Inc - Total Assets Trend (2012–2024)
This chart illustrates how Getein Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Getein Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Getein Biotech Inc's total assets of CN¥3.84 Billion consist of 50.1% current assets and 49.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.5% |
| Accounts Receivable | CN¥407.75 Million | 11.0% |
| Inventory | CN¥194.46 Million | 5.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥190.36 Million | 5.1% |
| Goodwill | CN¥309.71K | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Getein Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Getein Biotech Inc's current assets represent 50.1% of total assets in 2024, an increase from 48.0% in 2012.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2024, down from 22.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 11.0% of total assets.
Getein Biotech Inc Competitors by Total Assets
Key competitors of Getein Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Getein Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Getein Biotech Inc generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Getein Biotech Inc generates $6.03 in net profit.
Getein Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.32 | 1.90 | 3.22 |
| Quick Ratio | 2.14 | 1.69 | 2.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.31 Billion | CN¥ 963.75 Million | CN¥ 1.46 Billion |
Getein Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Getein Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.64 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -1.7% |
| Total Assets | CN¥3.71 Billion |
| Market Capitalization | $322.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Getein Biotech Inc's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Getein Biotech Inc's assets decreased by 1.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Getein Biotech Inc (2012–2024)
The table below shows the annual total assets of Getein Biotech Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.71 Billion | -1.70% |
| 2023-12-31 | CN¥3.77 Billion | +2.56% |
| 2022-12-31 | CN¥3.68 Billion | +17.19% |
| 2021-12-31 | CN¥3.14 Billion | +16.22% |
| 2020-12-31 | CN¥2.70 Billion | +34.49% |
| 2019-12-31 | CN¥2.01 Billion | +27.84% |
| 2018-12-31 | CN¥1.57 Billion | +23.99% |
| 2017-12-31 | CN¥1.27 Billion | +191.79% |
| 2016-12-31 | CN¥434.09 Million | +32.31% |
| 2015-12-31 | CN¥328.08 Million | +58.91% |
| 2014-12-31 | CN¥206.45 Million | +33.64% |
| 2013-12-31 | CN¥154.49 Million | +72.07% |
| 2012-12-31 | CN¥89.78 Million | -- |